BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript

BioCardia (BCDA) reported a Q3 2025 net loss of $1.5 million, ending the quarter with $5.3 million in cash, providing operational runway into Q2 2026. The company is actively enrolling patients in its confirmatory Phase 3 CardiAMP Heart Failure II study (BCDA-01) for ischemic heart failure and is pursuing regulatory approvals with Japan's PMDA and the FDA based on existing clinical data, with an FDA meeting request anticipated in Q4 2025. Additionally, BioCardia announced positive open-label results for its CardiAMP therapy in chronic myocardial ischemia (BCDA-02), showing significant improvements in exercise tolerance and angina, and expects nondilutive funding in Q1 2026 for its CardiALLO allogeneic stem cell therapy (BCDA-03). The company also plans a Q4 2025 FDA 510(k) submission for its Helix Biotherapeutic Delivery System.

Analysis

BioCardia (BCDA) reported a Q3 2025 net loss of $1.5 million, an improvement from $1.7 million in Q3 2024, alongside a reduced cash burn from operations. The company ended the quarter with $5.3 million in cash, which is projected to provide an operational runway into Q2 2026. This financial position is supported by a $6 million September financing and additional funds from its ATM program.

The company is making significant regulatory strides for its flagship CardiAMP cell therapy (BCDA-01) for ischemic heart failure, having received FDA Breakthrough Designation. BioCardia anticipates requesting an FDA meeting for approvability in Q4 2025 and expects a critical clinical consultation with Japan's PMDA in Q4, which could lead to a market entry submission. Concurrently, the confirmatory Phase 3 CardiAMP Heart Failure II study is actively enrolling, with four centers participating and three having randomized their first patients.

Beyond BCDA-01, BioCardia presented positive open-label results for BCDA-02 in chronic myocardial ischemia, demonstrating an 82% reduction in angina and an 80-second increase in exercise tolerance. The company also anticipates securing nondilutive funding in Q1 2026 for its CardiALLO allogeneic stem cell therapy (BCDA-03), potentially via NIH grants. Furthermore, a de novo 510(k) FDA submission for the Helix Biotherapeutic Delivery System is planned for Q4 2025, which could streamline future regulatory processes for its therapeutic programs.

Despite the optimistic outlook driven by clinical progress and regulatory engagement, the company acknowledges resource and bandwidth constraints as potential challenges for accelerating trial enrollment. The success of securing nondilutive funding for BCDA-03 and the ultimate outcome of regulatory discussions with the FDA and PMDA remain key determinants for BioCardia's near-term trajectory.

Key Decisions for Investors

• Monitor BCDA's regulatory interactions with the FDA and Japan's PMDA in Q4 2025, as these represent significant near-term catalysts for market entry and potential valuation upside.
• Evaluate the progress of the CardiAMP Heart Failure II trial enrollment and the securing of nondilutive funding for BCDA-03 in Q1 2026, which are crucial for pipeline advancement and reducing future dilution risk.
• Consider the company's cash runway into Q2 2026 and its ability to manage R&D expenses while advancing multiple clinical programs, as this will dictate future financing needs.